Otsuka subsidiary gets date with FDA for Lonsurf combo; Vaxcyte sells stock to bankroll PhIII vaccine trial
Otsuka subsidiary Taiho Oncology announced Tuesday morning that the FDA has accepted its application for a combo indication for Lonsurf, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
